Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like a pleasant morning to lift the spirits. A cool breeze and warm sun are enveloping the Pharmalot campus as we hunker down and sift through our ever-growing to-do list. A familiar exercise, yes? Well, time to get cracking. So please join us for a daily ritual — a few cups of stimulation — and do keep us in mind if you hear something fascinating. Meanwhile, here are your tidbits. Dig in and have a grand day. …
Pfizer (PFE) significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit, The Wall Street Journal says. The vaccine contributed $3.5 billion in revenue in the first three months of 2021 as the U.S. vaccination campaign kicked into high gear. Over the course of the full year, Pfizer now expects the vaccine to generate $26 billion in sales, up from an earlier forecast of $15 billion.
The European Medicines Agency has started a real-time review of the Sinovac Covid-19 vaccine, based on preliminary results from animal and human trials that suggested the vaccine produces an immune response against the coronavirus, Reuters writes. This is the first Chinese vaccine the EMA is studying in real-time, and the fourth Covid-19 vaccine under such a review, including those from CureVac (CVAC) and Novavax (NVAX) and Russia’s Sputnik V. The Sinovac vaccine has shown efficacy rates between 50% and 90% in different studies.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect